DRG Market Assessment reports

Characterized by an abnormal heart rhythm that starts in the atrial chambers, atrial fibrillation (AF) is the most common arrhythmia in clinical practice. Management of AF targets the prevention…

The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…

TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), and an IL-12/23 inhibitor (Johnson & Johnson Innovative Medicine’s…

Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns…

Painful diabetic neuropathy (PDN) afflicts more than three million people in the United States. It characterized by numbness, tingling, and burning, sharp, shooting or other painful sensations,…

Growth hormone deficiency (GHD) is characterized by slow growth or absence of growth, short stature, and absent or delayed sexual development. Accurately testing for GHD is challenging and often…

Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in…

Clarivate Epidemiology’s coverage of dementia comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of dementia for each country, as…

Giant cell arteritis (GCA) is an autoimmune disease marked by inflammation of blood vessels in the head and neck, especially the temporal arteries, leading to persistent headaches, flu-like…

A wide array of drugs is available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially…

The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem-cell disorders that disrupt normal hematopoiesis in the bone marrow. All pharmacological approaches to treating…